<sup>212</sup>Pb: Production Approaches and Targeted Therapy Applications
Over the last decade, targeted alpha therapy has demonstrated its high effectiveness in treating various oncological diseases. Lead-212, with a convenient half-life of 10.64 h, and daughter alpha-emitter short-lived <sup>212</sup>Bi (<i>T<sub>1/2</sub></i> = 1 h),...
Main Authors: | Konstantin V. Kokov, Bayirta V. Egorova, Marina N. German, Ilya D. Klabukov, Michael E. Krasheninnikov, Antonius A. Larkin-Kondrov, Kseniya A. Makoveeva, Michael V. Ovchinnikov, Maria V. Sidorova, Dmitry Y. Chuvilin |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-01-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/1/189 |
Similar Items
-
Rapid Elution of <sup>226</sup>Th from a Two-Column <sup>230</sup>U/<sup>226</sup>Th Generator with Diluted and Buffer Solutions
by: Stanislav V. Ermolaev, et al.
Published: (2023-04-01) -
A Novel Single-Step-Labeled <sup>212</sup>Pb-CaCO<sub>3</sub> Microparticle for Internal Alpha Therapy: Preparation, Stability, and Preclinical Data from Mice
by: Ruth Gong Li, et al.
Published: (2021-11-01) -
Preclinical Evaluation of a Lead Specific Chelator (PSC) Conjugated to Radiopeptides for <sup>203</sup>Pb and <sup>212</sup>Pb-Based Theranostics
by: Mengshi Li, et al.
Published: (2023-01-01) -
The Florida Bull Test 2008-2009
by: G. Cliff Lamb
Published: (2009-12-01) -
Coping with a Money Crunch: Values, Goals, and Standards
by: Katey Walker, et al.
Published: (2009-04-01)